Literature DB >> 21091283

Rapidly progressive dementias and the treatment of human prion diseases.

Brian S Appleby1, Constantine G Lyketsos.   

Abstract

IMPORTANCE OF THE FIELD: Rapidly progressive dementia (RPD) has many possible etiologies and definitive treatment is reliant upon an accurate diagnosis from an appropriate diagnostic work-up. A large portion of the neurodegenerative causes of RPD are due to prion diseases (e.g., Creutzfeldt-Jakob disease). The study of prion diseases, for which there is no currently available treatment, has public health implications and is becoming increasingly more relevant to our understanding of other protein misfolding disorders including Alzheimer's disease, frontotemporal degeneration, and Parkinson's disease. AREAS COVERED IN THIS REVIEW: This article begins with an overview of the etiologies and diagnostic work-up of RPD followed by a detailed review of the literature concerning the treatment of human prion diseases (1971 to present). WHAT THE READER WILL GAIN: The reader will understand the differential diagnosis and work-up of RPD as it pertains to its treatment, as well as an in-depth understanding of treatments of human prion diseases. TAKE HOME MESSAGE: An accurate diagnosis of the cause of RPD is of paramount importance when determining appropriate treatment. Most studies of the treatment for human prion diseases are case reports or case series, and results from only one randomized, placebo-controlled study have been reported in the literature (flupirtine). Studies have been hindered by disease heterogeneity and lack of standardized outcome measures. Although no effective prion disease treatment has been revealed through these studies, they provide important considerations for future studies.

Entities:  

Mesh:

Year:  2010        PMID: 21091283      PMCID: PMC3304579          DOI: 10.1517/14656566.2010.514903

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  84 in total

1.  Acyclovir in Creutzfeldt-Jakob disease.

Authors:  P K Newman
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

2.  Unsuccessful treatment of Creutzfeldt-Jakob disease with acyclovir.

Authors:  A S David; R Grant; J P Ballantyne
Journal:  Lancet       Date:  1984-03-03       Impact factor: 79.321

3.  Repeated suppression of Creutzfeldt-Jakob disease with vidarabine.

Authors:  T W Furlow; R J Whitley; F J Wilmes
Journal:  Lancet       Date:  1982-09-04       Impact factor: 79.321

4.  Unusual clinical course in a case of Creutzfeldt-Jakob disease.

Authors:  G Villa; C Caltagirone; G Macchi
Journal:  Ital J Neurol Sci       Date:  1982-07

5.  A protease-resistant protein is a structural component of the scrapie prion.

Authors:  M P McKinley; D C Bolton; S B Prusiner
Journal:  Cell       Date:  1983-11       Impact factor: 41.582

6.  [Amantadine in Creutzfeldt-Jakob disease. Review of the literature and case contribution].

Authors:  G Neri; L Figà-Talamanca; G C Di Battista; F Lo Russo
Journal:  Riv Neurobiol       Date:  1984 Jan-Mar

7.  The effect of amantadine on arousal and EEG patterns in Creutzfeldt-Jakob disease.

Authors:  M G Terzano; E Montanari; S Calzetti; D Mancia; A Lechi
Journal:  Arch Neurol       Date:  1983-09

8.  Novel proteinaceous infectious particles cause scrapie.

Authors:  S B Prusiner
Journal:  Science       Date:  1982-04-09       Impact factor: 47.728

9.  Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters.

Authors:  M Pocchiari; S Schmittinger; C Masullo
Journal:  J Gen Virol       Date:  1987-01       Impact factor: 3.891

10.  Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen.

Authors:  B Ehlers; H Diringer
Journal:  J Gen Virol       Date:  1984-08       Impact factor: 3.891

View more
  16 in total

1.  Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years.

Authors:  Martin C Michel; Piotr Radziszewski; Christian Falconer; Daniela Marschall-Kehrel; Koenraad Blot
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

Review 2.  Young-onset dementia epidemiology applied to neuropsychiatry practice.

Authors:  Bhargavi Devineni; Chiadi U Onyike
Journal:  Psychiatr Clin North Am       Date:  2015-03-26

3.  Lymphomatosis cerebri mimicking iatrogenic Creutzfeldt-Jakob disease.

Authors:  Elena Rivero Sanz; Miguel Ángel Torralba Cabeza; Francisco Sanjuán Portugal; Federico García-Bragado
Journal:  BMJ Case Rep       Date:  2014-09-08

Review 4.  Prions: Beyond a Single Protein.

Authors:  Alvin S Das; Wen-Quan Zou
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

5.  Prediction of antiprion activity of therapeutic agents with structure-activity models.

Authors:  Katja Venko; Špela Župerl; Marjana Novič
Journal:  Mol Divers       Date:  2013-09-20       Impact factor: 2.943

Review 6.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

7.  Polythiophenes inhibit prion propagation by stabilizing prion protein (PrP) aggregates.

Authors:  Ilan Margalith; Carlo Suter; Boris Ballmer; Petra Schwarz; Cinzia Tiberi; Tiziana Sonati; Jeppe Falsig; Sofie Nyström; Per Hammarström; Andreas Aslund; K Peter R Nilsson; Alice Yam; Eric Whitters; Simone Hornemann; Adriano Aguzzi
Journal:  J Biol Chem       Date:  2012-04-06       Impact factor: 5.157

Review 8.  Therapies for human prion diseases.

Authors:  Peter K Panegyres; Elizabeth Armari
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 9.  Comprehensive and Methodical: Diagnostic and Management Approaches to Rapidly Progressive Dementia.

Authors:  Supriya Mahajan; Brian S Appleby
Journal:  Curr Treat Options Neurol       Date:  2017-09-30       Impact factor: 3.598

10.  Evidence for inhibitory effects of flupirtine, a centrally acting analgesic, on delayed rectifier k(+) currents in motor neuron-like cells.

Authors:  Sheng-Nan Wu; Ming-Chun Hsu; Yu-Kai Liao; Fang-Tzu Wu; Yuh-Jyh Jong; Yi-Ching Lo
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-22       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.